PF-08634404 + ENFORTUMAB VEDOTIN for carcinoma, transitional cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Feb 2026: Trial registered, NCT07421700
  2. 11 Mar 2026: Trial started, NCT07421700

The trials

NCT07421700: Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

State
Under way
Phase
Phase 1 and Phase 2
People
132 planned
Started
11 Mar 2026
Primary completion
28 Dec 2027
Arms
Cohort B
Results
None posted
  1. 19 Feb 2026: Trial registered
  2. 11 Mar 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.